ENTRY       D01790                      Drug
NAME        Oxaliplatin (JAN/USAN/INN);
            Eloxatin (TN)
PRODUCT     ELOXATIN (Aventis Pharma) 98e269f3-fd0f-4415-bf73-0cf6a1907204
            OXALIPLATIN (Teva Parenteral Medicines) 9e51cc79-620c-48d7-b267-78e43c1ef6e4
            ELOXATIN (sanofi-aventis U.S. LLC) 3c740b43-f396-4998-bc66-6964a21f7161
  GENERIC   OXALIPLATIN (Actavis Pharma) 78f6a5f3-d088-4aee-9743-fa8cf19d3d75
            OXALIPLATIN (Alvogen) 69158776-cea7-505c-723b-e30117f29e89
            OXALIPLATIN (Apotex Corp.) ee5a5a1d-63f6-4d5a-901b-65be45ec6610
            OXALIPLATIN (Athenex Pharmaceutical Division) da19a970-f85c-4f13-8a45-6a673c23502e
            OXALIPLATIN (Breckenridge Pharmaceutical) 080a7c33-1106-464b-b52e-6ac97aca2d3d
            OXALIPLATIN (Breckenridge Pharmaceutical) 6400debf-ef77-48d7-a233-4cf252039e16
            OXALIPLATIN (Cipla USA) 5ffb166a-8283-44c0-8590-ecad2743c154
            OXALIPLATIN (Fresenius Kabi USA) e12e2850-4980-48de-af58-15e559fb921f
            OXALIPLATIN (Gland Pharma Limited) a6f89dc3-a594-4b5b-8728-272e20c1ecb5
            OXALIPLATIN (Gland Pharma Limited) d6178bc6-9dae-413f-8f47-de75d576c5b8
            OXALIPLATIN (Hospira) 80bb754d-38c2-483e-afae-b693f99896e8
            OXALIPLATIN (Hospira) e51a62ba-d163-4c57-835c-8c86cf097e40
            OXALIPLATIN (Meitheal Pharmaceuticals) 873fa936-157a-4f85-bc70-5df31d71d122
            OXALIPLATIN (Mylan Institutional LLC) 5023650b-d15b-4cce-a8cd-ccbdcd891f0c
            OXALIPLATIN (Mylan Institutional LLC) da0e8523-609a-4326-96b1-d7de78662d91
            OXALIPLATIN (NorthStar RxLLC) 36e7a154-759a-487b-b67f-6c605d017c7d
            OXALIPLATIN (Pfizer Laboratories Div Pfizer) b114b6c1-8a19-480c-8459-c23cbdc3516a
            OXALIPLATIN (Pfizer Laboratories Div Pfizer) e0890b0c-c1e9-4760-8914-0f28467d0e36
            OXALIPLATIN (Qilu Pharmaceutical) 33d4f4b4-bb4e-46af-9e89-df20154436d0
            OXALIPLATIN (Sagent Pharmaceuticals) 29a5d098-bfa7-4a65-bb4f-5daa1fef1c2f
            OXALIPLATIN (Sagent Pharmaceuticals) 6d020a9b-1244-45e5-b8d7-8342e85d7666
            OXALIPLATIN (Sandoz) 86f6c19d-30d1-42e3-8d46-5e3f45776e85
            OXALIPLATIN (Sandoz) ab162009-6f84-4d56-ab56-5e84409ec814
            OXALIPLATIN (Sanja Pharmaceuticals Company) 3c853336-2533-48ff-8b02-1bdbe196ed6b
            OXALIPLATIN (Sun Pharma Global FZE) 20910750-2bb6-4258-8368-df9ec207bfdd
            OXALIPLATIN (Sun Pharma Global FZE) 8efb4c07-455b-4c91-b257-6fd43854454c
            OXALIPLATIN (Winthrop U.S.) 70269278-fe61-4800-a064-32cb6845cc28
            OXALIPLATIN (Winthrop U.S.) a98b4070-822f-4fba-a844-690ff5556f0b
FORMULA     Pt. C6H14N2. C2O4
EXACT_MASS  397.0601
MOL_WEIGHT  397.2918
CLASS       Antineoplastic
             DG01679  Platinum compound
REMARK      Therapeutic category: 4291
            ATC code: L01XA03
            Chemical group: DG02187
ACTIVITY    Antineoplastic, Cell growth inhibitor
COMMENT     Platinum compound
            DNA alkylator
TARGET      DNA
METABOLISM  Transporter: SLC22A2 [HSA:6582], SLC22A1 [HSA:6580]
INTERACTION  
STR_MAP     map07040  Antineoplastics - alkylating agents
OTHER_MAP   map01524  Platinum drug resistance
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
              L01 ANTINEOPLASTIC AGENTS
               L01X OTHER ANTINEOPLASTIC AGENTS
                L01XA Platinum compounds
                 L01XA03 Oxaliplatin
                  D01790  Oxaliplatin (JAN/USAN/INN)
            Therapeutic category of drugs in Japan [BR:br08301]
             4  Agents affecting cellular function
              42  Antineoplastics
               429  Miscellaneous
                4291  Other Antitumors
                 D01790  Oxaliplatin (JAN/USAN/INN)
            Target-based classification of drugs [BR:br08310]
             Others
              Nucleic acid
               DNA
                Oxaliplatin
                 D01790  Oxaliplatin (JAN/USAN/INN)
            Cytochrome P450 interactions [BR:br08309]
             Transporter substrates
              SLC22A1
               Oxaliplatin
                D01790  Oxaliplatin (JAN/USAN/INN)
              SLC22A2
               Oxaliplatin
                D01790  Oxaliplatin (JAN/USAN/INN)
            Antineoplastics [br08340.html]
             D01790
            New drug approvals in the USA [br08319.html]
             New Molecular Entity and New Therapeutic Biological Product Approvals
              D01790
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D01790
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D01790
DBLINKS     CAS: 61825-94-3
            PubChem: 7848852
            ChEBI: 31941
            DrugBank: DB00526
            LigandBox: D01790
            NIKKAJI: J2.108.891I
ATOM        15
            1   O6a O    27.6304  -16.6769 #-
            2   C6a C    28.8402  -17.3773
            3   C6a C    30.0500  -16.6769
            4   O6a O    31.2599  -17.3773 #-
            5   O6a O    28.8402  -18.7782
            6   O6a O    30.0500  -15.2761
            7   C1x C    18.8079  -16.6698
            8   C1x C    18.8079  -18.0706
            9   C1x C    20.0240  -18.7710
            10  C1y C    21.2329  -18.0706
            11  C1y C    21.2329  -16.6698
            12  C1x C    20.0240  -15.9694
            13  N1a N    22.4327  -15.9781
            14  N1a N    22.4241  -18.7572
            15  Z   Pt   24.9608  -17.2359 #2+
BOND        13
            1     2   3 1
            2     3   4 1
            3     2   5 2
            4     1   2 1
            5     3   6 2
            6     7   8 1
            7     8   9 1
            8     9  10 1
            9    10  11 1
            10   11  12 1
            11   12   7 1
            12   11  13 1 #Up
            13   10  14 1 #Down
///
